Kellee Miller, United States of America
Jaeb Center for Health Research DiabetesPresenter of 1 Presentation
STRONG TREATMENT EFFECT OF CONTINUOUS GLUCOSE MONITORING (CGM) IN REDUCING HYPOGLYCEMIA IRRESPECTIVE OF PREVIOUS BLOOD GLUCOSE MONITORING AMONG OLDER ADULTS WITH TYPE 1 DIABETES (T1D)
Abstract
Background and Aims
The Wireless Innovation for Seniors with Diabetes Mellitus (WISDM) randomized clinical trial demonstrated reductions in hypoglycemia with CGM compared with blood glucose monitoring over 6 months among older adults with T1D. The aim of this analysis was to evaluate whether the treatment effect was influenced by the frequency of pre-study self-monitoring of blood glucose (SMBG).
Methods
203 older adults age ≥ 60 yrs were randomly assigned to use CGM or BGM for 26 weeks. CGM-measured outcomes stratified by baseline SMBG (<4x/d vs. >4x/d) were calculated at baseline (masked CGM) and during follow-up (masked CGM for BGM group).
Results
Among participants with baseline SMBG < 4 times/day, median percent time <70 mg/dL was reduced from 7.2% at baseline to 1.8% at 26 weeks in the CGM group and was 4.8% at baseline and 5.1% at 26 weeks in the BGM group. A positive treatment effect also was observed among participants with baseline SMBG ≥4 times/day (Table). After 26 weeks of CGM use, 78% and 85% of participants were using CGM six or more days/wk in those with baseline SMBG < 4 times/day and SMBG ≥4 times/day, respectively.
Conclusions
Prior to changing restrictions during the COVID-19 pandemic, public insurance (Medicare) for older adults in the US required SMBG ≥4 times/day for approval of CGM. These study results show CGM can be effectively used to reduce hypoglycemia irrespective of SMBG history.